Pharmaceutical companies have had a rough ride in the media over the last couple of years. Both Mylan Pharmaceutical and Turing Pharmaceutical have faced criticism for drug pricing, and Valeant Pharmaceuticals is under federal investigation for insurance fraud. But the news on firms isn’t all negative: Johnson & Johnson recently agreed to buy Abbott Medical Optics in a well-heralded deal.

In August, Mylan Pharmaceutical raised prices on its epinephrine autoinjector, the EpiPen, and since then, it has been mired in an extended PR crisis. Throughout, CEO Heather Bresch has remained on the defensive, first with parents of children with allergies, then the media, Congress, and most recently, its competitors.